ClinicalTrials.gg
RecruitingNCT05023018Updated Sep 15, 2026

NEO100 and High-Grade Meningioma

A Phase 2 interventional study of NEO100 in Residual, Progressive or Recurrent Grade II or III Meningioma, sponsored by Neonc Technologies, Inc.. Recruiting at 5 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Neonc Technologies, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Lymphoma, Follicular with a site in United States — 128 open to participants now, 217 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Planned enrollment
589th of 1,017
30 · median 38
Started
2022
with 35 others
Phase 2
379 of 1,187
34 open now
Primary completion
2026-12
later than 60 of 216 live
Registered
1,009th of 1,187
by date

Among the 1,187 studies in Lymphoma, Follicular with a site in United States, this one is the 589th largest by planned enrollment of the 1,017 interventional ones that give a count, is one of 36 that started in 2022, is one of 379 in phase 2, reaches primary completion later than 60 of the 216 other live ones, and was the 1,009th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

128 of the 1,187 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.

Read the detailed description

Meningiomas are the most common primary brain tumor with an incidence rate of 8.33 per 100,000. They originate from the meningeal (dural) coverings of the brain and spinal cord. Although the majority of meningiomas are benign, these tumors can grow slowly until they are very large, if left undiscovered, and, in some locations can be severely disabling and/or life-threatening.

There is a relative paucity of prospective clinical trials that provide an evidenced-based agreed upon approach to managing meningioma. Furthermore, uniformly applied guidelines have been difficult to achieve given the typical pattern of slow growth.

Meningiomas can be organized into two groups. WHO Grade I meningioma are histologically benign and can be managed by careful observation as recommended in the National Comprehensive Cancer Network Guidelines. Grade I meningiomas are low grade and have a 7-20% recurrence risk. For most other patients (WHO Grade II and WHO Grade III) there is an increased risk of recurrence and death. Grade II meningiomas occur in 5-15% of cases with a 30-40% recurrence risk and Grade III meningiomas occur 1-3% of the time with a 50-80% recurrence risk. For Grade I and Grade II meningiomas, gross total resection is standard. WHO Grade II and WHO Grade III meningiomas are referred to as high-grade meningiomas.

Questions remain regarding the selection and timing of treatment, especially in cases of recurrent meningioma or newly diagnosed high-grade meningioma (WHO Grade II or Grade III meningioma). For patients undergoing definitive therapy, complete resection (gross total resection) has been the standard. However, there is a significant subset of patients who are not successfully managed by surgery alone, or in whom a complete resection is not possible due to the relationship of the tumor to important anatomy. Complete tumor resection is not always achievable as many meningiomas arise at or near critical neural or vascular structures or in sites with limited surgical access When a gross total resection cannot be accomplished, post-operative radiation therapy is often considered (e.g., single-session stereotactic radiosurgery, hypofractionated stereotactic radiation therapy and conventionally fractionated external beam radiation therapy).

The potential for recurrence, whether following subtotal resection or gross-total resection, is well recognized. As a result, there is increasing evidence from retrospective review of case histories in support of radiation therapy as primary therapy for high-grade meningioma (or radiation prior to or following resection surgery). The relative efficacy of these approaches has not yet been tested in rigorously designed prospective clinical trials.

The role of chemotherapy in treating meningioma is also unclear; however, there is a need for additional therapeutic options to treat meningioma cases which cannot be managed by surgery and/or radiation therapy alone.

One reason for the hesitation to treat primary central nervous system tumours with chemotherapy is the difficulty of penetrating the blood brain barrier with chemotherapy agents. Nasal brain delivery of chemotherapy offers a novel, paradigm shifting platform based on technology to deliver chemotherapy via inhalation to the brain tumor. The presumed mechanism of nasal brain delivery from preclinical rodent studies is thought to be via the olfactory and trigeminal nerves. Effective nasal brain delivery has been demonstrated in humans in other diseases. For example, Reger et al. have reported effective delivery of intranasal insulin for Alzheimer's disease.

Perillyl alcohol, also called p-metha1,7-diene-6-ol,or 4-isopropenylcyclo-hexenecarbinol, is a monoterpene, isolated from the essential oils of lavender, peppermint, spearmint, and several other plants and synthesized by the mevalonate pathway. It has been previously demonstrated to have anti-cancer properties in preclinical studies in rodent models for a variety of cancers including mammary, pancreatic, and colon cancer. Although the exact mechanism of perillyl alcohol induced tumor regression is unknown, perillyl alcohol has been reported to modulate cellular processes that control cell growth and differentiation including G1 cell cycle arrest and induction of apoptosis.

Perillyl alcohol has also been shown to inhibit post-translational modification of proteins involved in signal transduction. It has been postulated that the anti-neoplastic activity of perillyl alcohol involves a decrease in the levels of isoprenylated Ras and Ras-related proteins, thereby reducing the physiological functioning of these proteins. Protein isoprenylation involves the post-translational modification of a protein by the covalent attachment of a lipophilic farnesyl isoprenoid group to a cysteine residue at or near the carboxyl terminus. Isoprenoid substrates for prenylprotein transferase enzymes include farnesyl pyrophosphate plus geranylgeranyl pyrophosphate, two intermediates in the mevalonate pathway. This action was attributed to the inhibition of farnesyl protein transferase activity. Farnesylation is the most critical part of the process that leads to the activation of Ras, and farnesyl transferase inhibitors exert their antitumor effect in part by inhibiting Ras-mediated signaling. A study revealed that H-Ras and K-Ras farnesylation were inhibited by perillyl alcohol.

Ras activity is elevated in malignant central nervous system tumors. Strong evidence demonstrates that Ras protein is highly expressed in meningioma cells, and inhibition of Ras activity may inhibit the growth of meningiomas. Activated Ras stimulates other pathways essential for proliferation and progression through the cell cycle and inhibition of apoptosis in malignant gliomas. Moreover, the formation of malignant meningioma may require the cooperation of both Ras and Akt signaling. This cooperative effect has been demonstrated by somatic-cell gene transfer, during which transfer of either an activated form of K-Ras or Akt alone to neural progenitors was insufficient to form malignant glioma in vivo, but the combined effect of both pathways could initiate gliomagenesis. Thus, based on this potential alteration in signal transduction involving K-Ras in malignant central nervous system tumors, and its ability to induce cell cycle arrest and apoptosis, perillyl alcohol (NEO100) may be an attractive agent and warrants further clinical development. Furthermore, intranasal delivery of NEO100 has the additional, potential benefit of direct drug delivery into the brain and avoiding systemic toxicity and first pass metabolism.

Intranasal delivery of NEO100 will directly penetrate meningiomas, particularly skull-based meningiomas which extend along the olfactory groove, tuberculum sella, spenoid ridge and petroclival region. These represent some of the most challenging pathologies encountered by neurosurgeons due to the meningioma depth, invasion, vascularity and relationship to critical cranial nerves and vessels.

Intranasal perillyl alcohol has been tested in a Phase I clinical trial in the US, it has also been studied in two clinical studies in Brazil in more than 275 patients with systemic cancers and in malignant glioma. The Brazil studies indicate good tolerance and no long term central nervous system (CNS) or systemic severe adverse events. Adult patients with CNS cancers received commercial (Sigma Chemical) perillyl alcohol (formulated as a 10% solution in ethanol:glycerol) administered intranasally via a commercial nasal delivery mask four times a day (110 mg/dose or 440 mg/day). Radiographic regression and a PFS-6 of 50% were reported. A pharmacokinetic study showed that perillic acid, a metabolite of perillyl alcohol, was detected in the serum of patients 30 minutes post inhalation after a single dose of 110 mg or 220 mg of perillyl alcohol and lasted for 3 hours.

03

Conditions studied

  • Residual, Progressive or Recurrent Grade II or III Meningioma

Keywords

  • Residual, Progressive or Recurrent Grade II or III Meningioma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient must:

  1. Have confirmed WHO Grade II or III meningioma that is residual, progressive or recurrent following at least minimally safe resection and radiation therapy. meningiomas are allowed.

    1. Residual disease is defined as residual (without a requirement for progression). Residual measurable disease is defined by bidimensionally measurable lesions with clearly defined margins by MRI scan(s) with a minimum diameter of 10mm in both dimensions.
    2. Progressive disease is defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area). The change must occur between scans separated by no more than 24 months.
    3. Recurrent disease is defined as new evidence of measurable disease following complete resection (10mm in both dimensions).
  2. Be on a stable or decreasing dose of for at least five days prior to the date of .
  3. Participants must have failed maximal safe resection and radiation therapy.
  4. There is no limit on the number of prior surgeries, radiation therapy, radiosurgery treatments or systemically administered therapeutic agents, however, these treatment(s) must comply with the following:

    1. There is no limit on the number of prior therapies.
    2. Prior medical therapy is allowed but is not required.
    3. No chemotherapy, other agents within 14 days of study treatment.
    4. For prior systemic agents, participants must be at least 4 weeks (or 5 half-lives, whichever is shorter) from other prior cytotoxic chemotherapy (6 weeks from nitrosoureas/alkylating agents) or biologic therapies.
    5. No other concurrent receipt of investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study.
    6. Patients may have been treated with standard external beam radiation or radiosurgery in any combination; however an interval of ≥12 weeks (84 days) must have elapsed from the completion of the radiation therapy to the initiation of study therapy unless there is histopathologic confirmation of recurrent tumor or there is new enhancing tumor outside the radiation field (beyond the high dose region or the 80% isodose line). In addition, there must be subsequent evidence of tumor progression after completion of radiation therapy;
    7. An interval of ≥ 28 days and full recovery (no ongoing safety issues) from surgical resection is required;
    8. Meningiomas that have resulted from prior radiation therapy are allowed.
    9. There must be an interval of ≥ 7 days from stereotactic ; and
  5. Participants must have recovered to grade ≤1 or pretreatment baseline from adverse events related to prior therapy (exclusions include, but are not limited to alopecia, laboratory values listed per inclusion criteria and lymphopenia)
  6. Patient must be ≥ 12 years of age.
  7. Patient must have an performance status of 0-2 or ≥ 60.
  8. Patient must have an expected survival of at least three months.
  9. Patient must be willing to provide blood sample for pharmacokinetic study (to assess proper administration of NEO100).
  10. Patient must have adequate organ and marrow function as defined below:
  11. White blood cell (WBC) ≥2000/microliter
  12. (ANC) ≥ 1,500/microliter
  13. ≥ 100,000/microliter
  14. ≥9 gm/dl
  15. (SGOT)/ALT (SPGT) ≤ 2.5 × laboratory (ULN)
  16. Serum creatinine ≤ 1.5 x laboratory upper limit of normal (ULN) or
  17. (meas or calc) ≥60mL/min for participants with creatinine levels >1.5x laboratory upper limit of normal (ULN)
  18. Total serum ≤ 1.5 x laboratory upper limit of normal (ULN) except participants with Gilbert's Syndrome who can have a total serum bilirubin of \<5 x laboratory upper limit of normal (ULN)
  19. MRI (or CT if MRI ) within 14 days prior to start of study drug. Corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan. If steroids are added or the steroid dose is increased between the date of the screening scan and the start of treatment, a new baseline scan is required.
  20. Female patients of and male patients must agree to use adequate (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first administration of study drug, for the duration of study participation, and for 90 days following completion of therapy. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  21. A female of child-bearing potential is any woman (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    1. Has not undergone a hysterectomy or bilateral oophorectomy; or
    2. Has not been naturally for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  22. A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to initiating study drug.
  23. A serum pregnancy test will be repeated immediately if pregnancy is suspected.
  24. Women must not be breastfeeding.
  25. Patient must have the ability to understand, and the willingness comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study as confirmed by signing a written informed consent document.

Exclusion criteria

Exclusion Criteria

  1. Patients who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days (or 5 half-lives, whichever is shorter) of study treatment.
  2. Patient has completed chemo-radiation within the last 84 days prior to the first administration of study drug, unless new contrast enhancement is outside of radiation field, or there is tissue proven recurrence or progression.
  3. Patient has had surgery within seven days prior to the date of .
  4. Patient has had cytotoxic chemotherapy within 4 weeks (or 5 half-lives, whichever is shorter), nitrosoureas/alkylating agents within 6 weeks or biologic therapies.
  5. Prior treatment with interstitial brachytherapy within 6 months of start of study therapy.
  6. Current or planned participation in a clinical trial of an agent or using an investigational medical device.
  7. The patient's disease is primarily localized to the brainstem or spinal cord;
  8. Patient has not recovered from adverse events due to chemotherapy, immunotherapy, or radiation therapy.
  9. Patient has had prior treatment with perillyl alcohol.
  10. Patient has a history of allergic reactions attributed to perillyl alcohol.
  11. Patient has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  12. Patient must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
  13. Patient has a history of new diagnosis or treatment of cancer other than high-grade meningioma within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.
  14. of the patient's tumor.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Patients with high-grade meningioma

    30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma

    Drug: NEO100

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival as six months (PFS6).

    Progression free survival

    Time frame: 6 months

Secondary outcomes

  1. Objective Tumor response to NEO100 as determined by RANO criteria

    Time frame: 6 months

  2. Overall survival

    Time frame: 12 months

  3. Perillic acid measurement

    Time frame: 30 days

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.

Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's planned 53 months is above that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2021
First posted
Aug 26, 2021
StartActual
Jul 1, 2022
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05023018
Lead sponsor
Neonc Technologies, Inc.
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
Jul 1, 2022
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Chris Beardmore
Contact
chris@anovaevidence.com
224 218 2408
Chloe Richmond
Contact
chloe@anovaevidence.com
224 218 2408
Tom Chen, MD, PhD
study chair · NeOnc Technologies
Josh Neman
study director · NeOnc Technologies Holdings, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perillyl alcohol

Start the discussion